DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently prescribed early-line treatments for POS are generic mainstays, such as levetiracetam, lamotrigine, and carbamazepine/oxcarbazepine; newer brands such as Vimpat and Briviact are prescribed in later lines of therapy, mostly to treatment-refractory patients. Neurologists consider many factors when selecting among the many first-, second-, and third-generation AEDs and make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving journey of epilepsy patients with POS provides important context about the complex, saturated, and heavily generic market that developers of new AEDs will enter. For the first time, our 2019 Treatment Algorithms series offers this POS segmentation, as well as a companion study on generalized-onset seizures (GOS).
- What patient share do key generics and brands garner by line of therapy in newly diagnosed epilepsy patients with POS? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy patients with POS?
- How have Briviact, Vimpat, and other third-generation brands been integrated into the treatment algorithm, and what is their source of business?
- What proportion of newly diagnosed epilepsy patients with POS receive drug therapy during our tracking period, and how quickly do they receive it? What percentage of patients progress to later lines of therapy during our tracking period?
- What percentage of epilepsy patients with POS are treated with monotherapy versus combination therapy? What are the most commonly used therapy combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with POS?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Sunovion Pharmaceuticals, Eisai, UCB, Pfizer, Janssen, and Concordia Pharmaceuticals
Key drugs covered: Vimpat, Aptiom, Briviact, Fycompa, Lyrica, levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, valproates
Key analysis provided:
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Epilepsy - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)
- Treatment Algorithms CDA-Epilepsy (Partial-onset seizures)-US-April 2019
Author(s): Niyati Khetarpal, Ph.D
"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”